Biocon wins USFDA approval for cancer biosimilar Pebrilzo
In short
Biocon has got USFDA approval for Pebrilzo, its fifth cancer biosimilar. The company also said it has a global settlement and licence deal with Genentech.
That agreement allows Pebrilzo's earliest licensed US launch in 2028. It gives Biocon a clearer route to sell the drug in the US.
What the reporting says
Biocon secured USFDA approval for Pebrilzo, its fifth cancer biosimilar, and said it has a global settlement and licence agreement with Genentech. The deal allows Pebrilzo's earliest licensed US launch in 2028. The approval and agreement strengthen Biocon's biosimilar pipeline and set a clearer path for the drug's US rollout.
Why it matters
Biocon received USFDA approval for Pebrilzo and said it reached a global settlement and licence agreement with Genentech. The agreement sets up the earliest licensed US launch for 2028, giving the company a defined path for a later market entry. The news is important for Biocon's biosimilar portfolio and its cancer treatment pipeline.